© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options.
Study results underline the importance of treating hepatitis C virus.
Investigators wanted to see if blinatumomab could increase survival rates free from leukemia and be less toxic than intensive chemotherapy.
90% to 100% of study participants achieved complete or partial responses to treatment.
Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
